Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Qualigen posts positive readout in triple negative breast cancer in vivo model

Qualigen Therapeutics (NASDAQ:QLGN) completed its in vivo efficacy analysis of QN-247 in solid tumors, with data demonstrating robust efficacy and no safety signals in a triple negative breast cancer (TNBC) model...

August 2, 2022

Markets

Maxim starts scPharmaceuticals at buy; PT $10

Maxim Group initiated coverage of scPharmaceuticals (NASDQ:SCPH) with a “buy” rating and price target of $10. The stock closed at $4.89 on Aug. 2. scPharmaceuticals is a late-stage pre-commercial company developing...

August 2, 2022

Markets

Cantor starts Clever Leaves at OW; PT $4.50

Cantor Fitzgerald initiated coverage of Clever Leaves Holdings (NASDAQ:CLVR) with an “overweight” rating and $4.50 price target. The stock closed at 92 cents on July 27. “In relative terms, the stock offers better ‘pure...

August 1, 2022

Markets

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Tonix Pharmaceuticals (NASDAQ:TNXP) is collaborating with the Kenya Medical Research Institute to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop Tonix’s TNX-801 as a vaccine...

July 28, 2022

Markets

Cantor downgrades ObsEva on restructuring and likely CRL

Cantor Fitzgerald downgraded ObsEva (NASDAQ:OBSV) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company announced a corporate restructuring and refocus of its development and...

July 28, 2022

Developments

NeuroSense, NeuraLight in pact to detect ALS oculometric biomarkers

NeuroSense Therapeutics (NASDAQ:NRSN) and closely-held NeuraLight are collaborating to advance the science of digital biomarkers in the detection and monitoring of neurological diseases, including amyotrophic lateral...

July 28, 2022

Developments

NervGen NVG-291-R posts significant preclinical functional repair from stroke

The University of Cincinnati and Case Western Reserve University published a pioneering preclinical study in the peer-reviewed scientific journal, Cell Reports, demonstrating that NervGen Pharma‘s (TSXV:NGEN;...

July 28, 2022

Developments

Palisade Bio screens first patient in Phase 3 bowel function trial

Palisade Bio (NASDAQ:PALI) screened the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With the first U.S...

July 27, 2022

Developments

180 Life Sciences, U of Oxford to study post operative delirium

A team led by researchers at University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) in the U.K. to conduct a feasibility trial to investigate whether anti-tumor...

July 27, 2022

Markets

BTIG starts Keros at buy; PT $80

BTIG launched coverage of Keros Therapeutics (NASDAQ:KROS) with a “buy” rating and $80 price target. The stock closed at $28.53 on July 25. Analyst Julian Harrison writes that following Acceleron’s impressive foray into...

July 26, 2022

Markets

Maxim upgrades Agile on financing and contraceptive tailwind

Maxim Group upgraded Agile Therapeutics (NASDAQ:AGRX) to “buy” from “hold” and set a $1 price target, after the company closed a recent equity offering, enacted austerity measures and refined its commercial efforts. The...

July 26, 2022

Developments

VistaGen fails Phase 3 trial in social anxiety disorder

VistaGen Therapeutics’ (NASDAQ:VTGN) topline results from its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder did not achieve its primary endpoint, as...

July 22, 2022

Qualigen posts positive readout in triple negative breast cancer in vivo model

Maxim starts scPharmaceuticals at buy; PT $10

Cantor starts Clever Leaves at OW; PT $4.50

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Cantor downgrades ObsEva on restructuring and likely CRL

NeuroSense, NeuraLight in pact to detect ALS oculometric biomarkers

NervGen NVG-291-R posts significant preclinical functional repair from stroke

Palisade Bio screens first patient in Phase 3 bowel function trial

180 Life Sciences, U of Oxford to study post operative delirium

BTIG starts Keros at buy; PT $80

Maxim upgrades Agile on financing and contraceptive tailwind

VistaGen fails Phase 3 trial in social anxiety disorder

General

More